Amgen buys DeCode Genetics for $415M
Biotech giant Amgen is buying Icelandic genetics research firm DeCode Genetics for $415 million, the Thousand Oaks company said Dec. 10. The all-cash deal is expected to close before the end of the year and will give Amgen, the largest biotechnology firm in the world, opportunities to develop new medicines that target defective DNA. “DeCode Read More →
Vitesse to raise $16.1M in stock offering
Camarillo-based Vitesse Semiconductor plans to raise $16.1 million in a public offering of stock. The deal, announced Dec. 6, will offer 10 million shares at $1.75 each, netting $16.1 million after costs. It’s expected to close Dec. 12. Needham & Company is acting as the sole book-running manager of the offering, and Craig-Hallum Capital Group Read More →
DeLorenzo leaves Dole for Itochu
Dole Food Co. President and CEO David DeLorenzo is leaving the company to lead Itochu Corp., the Japanese firm that’s in the process of buying Dole’s packaged foods unit for $1.7 billion. In another step toward closing the Itochu deal by the end of the year, shareholders of the Westlake Village-based food company approved it Read More →
Vitesse tees up stock offering
Camarillo-based Vitesse Semiconductor is planning a stock offering despite years of losses and a shareholder base that’s underwater in terms of book value. Vitesse said Dec. 6 that it plans an offering that will be underwritten by Needham & Company as the sole bookrunning manager of the offering and Craig-Hallum Capital Group as co-manager. The Read More →
Amgen aims to put cholesterol drug on market
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen case before SCOTUS could stymie new class-action suits
On Nov. 5, Thousand Oaks-based Amgen argued a case before the U.S. Supreme Court that could make it much harder for shareholders to form a class when suing a company for making misleading statements that distort its stock price. The outcome, which is likely to be decided by the politics of the individual justices, could Read More →
